Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03867357 · ClinicalTrials.gov registry record
Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia
A clinical trial, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Completed
- Registry status
- 60
- Enrollment target
NCT03867357: Completed study, sponsored by Seattle Institute for Biomedical and Clinical Research.
NCT03867357 is a clinical trial that has completed, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03867357 has completed, sponsored by Seattle Institute for Biomedical and Clinical Research.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
Prostate cancer (PCa) is the most common cancer among men and is even more common in the military and veteran population. For patients with advanced prostate cancer, the most common treatment includes lowering the levels of the hormone testosterone as much as possible. This is called "androgen deprivation therapy" or "ADT". Unfortunately, ADT also causes patients to be fatigued, weak and to loose muscle. This is often referred to as "sarcopenia" and it leads to falls, poor quality of life and higher risk of death. Currently, there is no treatment for sarcopenia because the investigators do not understand the mechanisms that cause it. The mitochondria is the part of the cells responsible for providing energy to muscles but to this date the investigators do not know if it is affected in prostate cancer patients with sarcopenia due to ADT. The overall goal of this proposal is to establish if the mitochondria is responsible for sarcopenia in patients with prostate cancer receiving ADT. The investigators will measure mitochondrial function, muscle mass and strength, and feelings of fatigue and quality of life in patients with prostate cancer before starting and after 6 months of ADT.
Primary Outcome
Changes in LBM (kg) measured by X-ray densitometry (DEXA).
Interventions
- DRUG GnRH agonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-12-07 |
| Est. Completion | 2023-09-01 |
What the finished NCT03867357 record still lists
NCT03867357 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which GnRH agonist is the first listed.
NCT03867357 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03867357 about?
NCT03867357 is a clinical study titled "Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia". Prostate cancer (PCa) is the most common cancer among men and is even more common in the military and veteran population. For patients with advanced prostate cancer, the most common treatment includes lowering the levels of the hormone testosterone as much as possible. This is called "androgen depri...
What is the current status of trial NCT03867357?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2018-12-07. Estimated completion is 2023-09-01.
What interventions are being tested in trial NCT03867357?
The interventions under investigation include: GnRH agonist (DRUG).
Who is sponsoring clinical trial NCT03867357?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI